MGO for neurodegenerative disorders and aging

New Species Independent Competitive Assay for MGO!

Why measure MGO?

  • Methylglyoxal (MGO) is a highly potent glycating metabolite which is produced during glycose, amino acid as well as fatty acid metabolism.
  • MGO forms covalent adducts with the side chains of lysine-, cysteine- and arginine-residues, which is classified as an early glycation process and occurs in all tissues and body fluids. 
  • Subsequent, later-stage reactions result in the formation of advanced glycation end products termed  AGEs (Advances Glycation Endproducts).
  • The damaging effect of MGO consist of the covalent cross-linking of proteins, or when the modified amino acid is located in the active site of the enzyme or results in a structural rearrangement of the modified protein.
  • In order to counteract the damaging effect of MGO our body has evolved several non-enzymatic as well as non-enzymatic defensis such as the glyoxalase system.
  • In C. elegans silencing of the glyoxalase system resulted in a decreased lifespan by 40%. In human, increased production and accumulation of methylglyoxal (MGO) are hallmarks of aging and a number of pathological conditions such as  neurodegenerative disorders and diabetes.

Specifications of the assay:

  • Assay time: 3.5 hours
  • Species independent
  • Sample types tested: plasma, serum, urine and faeces
  • HIT503 standard consists of MGO labelled HSA (µg/ml)
  • Detection limit: 7.8µg/ml HSA-MGO equivalents.
  • Dynamic range: 7.8 – 500µg/ml HSA-MGO equivalents.
  • Sample volume: 125µl/well

Measurement of MGO in plasma samples:

MGO in plasma samples

Species independent assay!

Species independent measurement

Contact us